{
    "clinical_study": {
        "@rank": "148258", 
        "brief_summary": {
            "textblock": "The objective of this study is to demonstrate the safety and efficacy of IC14 in the\n      treatment of hospitalized patients with community-acquired pneumonia and sepsis."
        }, 
        "brief_title": "A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis", 
        "condition": [
            "Pneumonia", 
            "Sepsis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Pneumonia", 
                "Sepsis", 
                "Toxemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Current diagnosis of community-acquired pneumonia.\n\n          -  Evidence of systemic inflammatory response to infection.\n\n        Exclusion Criteria:\n\n          -  Atypical or viral pneumonia based on clinical or epidemiologic suspicion by the\n             investigator.\n\n          -  Presence of organ failure."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "August 1, 2002", 
        "id_info": {
            "nct_id": "NCT00042588", 
            "org_study_id": "EPN01", 
            "secondary_id": "EPN01"
        }, 
        "intervention": {
            "intervention_name": "Recombinant Chimeric Monoclonal Antibody", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "keyword": [
            "Safety and Efficacy", 
            "Community-Acquired Pneumonia, Sepsis"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bothell", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98021"
                }, 
                "name": "ICOS Corporation"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00042588"
        }, 
        "source": "ICOS Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ICOS Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2004"
    }, 
    "geocoordinates": {
        "ICOS Corporation": "47.762 -122.205"
    }
}